The COVID crisis has laid bare the inequities faced by certain populations in our health care system. It has become increasingly clear that the drug development process for a whole host of diseases often leaves these same populations behind through their absence or underrepresentation in clinical trials. This episode evaluates the problem and looks for ways to improve the process so that medicines and vaccines work for everyone who takes them.
